Please cite this article as: Velenik V, Ocvirk J, Oblak I, Anderluh F. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancerlocated within 5 cm from the anal verge. Non-fatal perioperative complications occurred in 13 patients (35%) with delayed wound healing occurring in 6 patients (16%). One death was recorded due to sepsis following colonic necrosis.
Methods
Patients with stage II/III LARC received capecitabine 1250 mg/m 2 twice daily for 2 weeks followed by intravenous cetuximab 400 mg/m 2 at week 3, then weekly intravenous 250 mg/m 2 cetuximab plus CRT including capecitabine 825 mg/m 2 twice daily (including weekends during radiotherapy) with radiotherapy of 45 Gy (25 x 1.8 Gy), 5 days a week for 5
weeks. Total mesorectal excision was scheduled 4-6 weeks following completion of CRT.
The primary endpoint was pathological complete response (pCR).
Results
Thirty-seven patients were eligible for safety and efficacy. TMN staging at baseline was: T4N2, 11%; T3N2, 40%; T2N2, 3%; T3N1, 35%; T2N1, 3% and T3N0 8%. The most common adverse events included, grade 1/2 acneiform skin rash (86%), and grade 3 radiodermatitis, (16%), diarrhea (11%) and hypersensitivity (5%). pCR was achieved in 3 patients (8%). Overall-, T-and N-downstaging rates were 73%, 57% and 81% respectively.
Total sphincter preservation rate was 76%, and 53% in 17 patients whose tumors were
Introduction
Multimodal treatment strategies aim to reduce tumor recurrence rates and improve survival in patients with resectable locally advanced rectal cancer (LARC). Pre-and postoperative radiotherapy are reported to decrease the risk of local relapse in this setting. [1] [2] [3] Chemotherapy in combination with radiotherapy can act as a radiosensitizing agent, potentially eradicating micrometastases. The combination of postoperative 5-fluorouracil (5-FU)-based chemotherapy with radiation in the treatment of LARC is reported to improve patient disease-free survival (DFS) and overall survival. 4 Lower rates of local regional failure (13% vs. 6%) in patients receiving preoperative 5-FU-based chemoradiotherapy (CRT) compared with postoperative 5-FU-based CRT have also been demonstrated. 5 The addition of continuous infusion (CI) 5-FU-based chemotherapy concurrently to preoperative long-term fractionation radiation is now considered by many to be the standard of care for LARC patients in Europe, following data from prospective randomized studies. 6, 7 However, whilst rates of pathological complete response (pCR) and local control were found to be higher in the CRT arms than radiotherapy alone arms, no significant improvements to DFS or overall survival were found, with the occurrence of metastatic disease remaining a problem. [6] [7] [8] Thus new combinations of chemotherapeutic agents for CRT in LARC patients are urgently sought.
Capecitabine (Xeloda, Hoffmann-La Roche Ltd, Basel Switzerland) an oral fluoropyrimidine prodrug is readily absorbed into the gastrointestinal tract and activated primarily in tumor cells displaying high levels of thymidine phosphorylase. 9 Capecitabine has the same efficacy as CI 5-FU but with less of the associated toxic side effects, 9, 10 and has demonstrated radiosensitizing properties in vivo. 11 Furthermore when capecitabine was administered concomitantly with radiotherapy to LARC patients in phase II studies, low toxicity profiles, tumor downstaging and pCR rates ranging from 4-31% were reported. 12, 13 EGFR expression has been associated with reduced DFS in patients with LARC following preoperative CRT. 19, 20 Thus EGFR-targeted agents appear to be attractive candidates for use with CRT in this setting. Recent phase I/II studies have reported acceptable toxicity and tumor downstaging when cetuximab was administered in combination with fluoropyrimidinebased CRT in rectal cancer patients. 21, 22 In the present study the addition of cetuximab to capecitabine-based CRT was investigated in the neoadjuvant treatment of resectable LARC patients. 
Patients and Methods

Study design
Patient treatment
A summary of the study treatment is shown in Figure 1 . Patients received capecitabine 1250 mg/m² twice daily for 2 weeks. Cetuximab 400 mg/m 2 was intravenously administered on week 3, followed by 250 mg/m 2 /week during radiotherapy. Radiotherapy started on week 4
and was delivered once a day using 15 MV photon beams and a four-field box technique, 5 days a week. The small pelvis received 45 Gy in 25 fractions of 1.8 Gy over 5 weeks. Threedimensional conformal CT-based treatment planning was performed. The clinical target volume (CTV) encompassed the primary tumor, entire mesorectal tissue, and internal iliac and presacral lymph nodes up to the L5/S1 junction and 5 cm distal to the primary tumor. An additional 1 cm in all directions was added to the CTV to obtain the planning target volume (PTV). During irradiation, patients were treated in the prone position, with a full bladder, and a belly-board immobilization device was used. A multileaf collimator was used for shaping the fields and for the protection of normal tissues. Chemotherapy was administered concomitantly with radiotherapy and consisted of capecitabine administered orally at a daily dose of 1650 mg/m 2 , divided into two equal doses given 12 hours apart, one administered an hour prior to irradiation. Chemotherapy was started on the first day and finished on the last day of radiotherapy (including weekends).
Patient and tumor assessments
During treatment, patients were evaluated weekly. Clinical examinations and complete blood counts were performed and body weight was measured. Toxic side effects were assessed according to National Cancer Institute Common Toxicity Criteria (NCI-CTC version 3.0).
Following re-evaluation of the primary tumor with pelvic MRI and an assessment of tumor response as defined by RECIST criteria, definitive surgery was scheduled for 6 weeks after the completion of CRT. Surgical management included a sphincter preservation approach whenever possible, using the total mesorectal excision (TME) technique. The option for a temporary colostomy during surgery was left to the surgeon's discretion.
Postoperative, pathological evaluation of the surgical specimen was performed. Pathological complete response was defined as the complete disappearance of all tumor cells.
Histological regression of the primary tumor was semi-quantitatively determined according to a 5 scale tumor regression grading (TRG) 23 
Postoperative chemotherapy
Postoperative adjuvant treatment with capecitabine for 3 cycles starting within 6 weeks after surgery was recommended. A three-week cycle consisted of 2 weeks of capecitabine treatment (1250 mg/m 2 twice-daily) followed by a 1 week treatment break.
Statistical considerations
The primary endpoint of the study was the pCR rate. At the time of the study design the reported pCR for neoadjuvant capecitabine-based CRT in LARC ranged from 4-31%,
including 9% from our previously reported phase II trial. 13 The aim was to evaluate whether a 26% pCR rate was achievable by adding cetuximab to standard preoperative treatment. 
Results
Patient characteristics
Forty-three patients with resectable primary LARC were recruited between February 2007
and September 2008. One patient did not receive study treatment due to the detection of metastatic disease during the pretreatment work-up. One patient withdrew consent following three weeks of treatment, and another was excluded due to protocol violation. Table 1 . The most frequent MRI staging was uT3N+ (75%). In 18 patients the primary tumor was sited 5 cm or less from the anal verge.
Acute toxicity and treatment compliance
Neoadjuvant treatment with cetuximab was discontinued after the first administration in 4/37 patients due to hypersensitivity reactions. These patients were subsequently treated with capecitabine and radiation only. For one patient 2 doses of cetuximab were omitted due to grade 3 hepatotoxicity. All patients received the planned dose of radiation. The median duration for radiotherapy treatment was 33 days (range 33−43 days). The median time of interruption to radiotherapy treatment was 2 days (range 1−7 days) and occurred in 30
patients, due to treatment-related toxicity (4 patients) or mechanical failure/ holiday period (26 patients). The median duration of chemotherapy with capecitabine during radiotherapy was 33 days (range 33−43 days) and the median time of chemotherapy interruption was 6 days (range 1−11 days). Only two patients received less than 90% of the planned capecitabine dose due to grade 3 hepatotoxicity, (one patient) and grade 3 diarrhea, (one patient). The relative dose intensity for cetuximab, capecitabine and radiotherapy was 91%, 98% and 100% respectively.
The frequency and grade of treatment-related acute toxicities are summarized in Table 2 .
The most frequent side-effect of CRT was grade 1/2 acneiform rash. The most frequent grade 3 adverse event was radiodermatitis. During the treatment period, 22 patients lost weight compared with the beginning of treatment. The maximum body weight loss was 19% (median 5%). Of the remaining patients, eight succeeded in maintaining a constant weight, and nine patients experienced a weight increase of up to 6% (median 1%).
Surgery and perioperative toxicity
A summary of patient surgery and perioperative toxicity is shown in Table 3 . All patients underwent definitive surgery following neoadjuvant therapy and were operated on between No perioperative deaths were recorded within one month following surgery. Non-lethal perioperative complications were recorded in 13 patients, with the most common cause due to wound healing problems ( Table 3) . Two patients required further operations (one patient for anastomotic leakage and abdominal abscess, and one patient for an incarcerated transversostoma).
Efficacy
Pathological TNM stages, as assessed on histopathological examination of resected specimens, in relation to preoperative TNM status, are presented in 
Preservation of the anal sphincter
Prior to therapy, abdominoperineal resection was planned in 11/37 patients who had definitive surgery. Following completion of CRT, sphincter preserving surgery was successfully performed in two of these patients. The SPR was 76% (28/37 patients) and in the subgroup of 17 patients with tumors located within 5 cm of the anal verge, sphincter preservation was possible in nine patients. 
Discussion
Neoadjuvant cetuximab plus CRT on tumor response in LARC
In this phase II study the addition of cetuximab to capecitabine and radiotherapy in the neoadjuvant treatment of LARC patients led to a pCR rate of 8% and a high rate (73%) of pathological downstaging of tumors. The pCR rate is similar to that reported in a phase I/II study in Belgian LARC patients, (5%), where a lower rate of pathological tumor downstaging (38%) was recorded. 22 Similar doses of cetuximab and CRT were used in the two studies, however in the current study capecitabine was administered twice daily at 1250 mg/m 2 for two weeks, three weeks prior to radiotherapy whereas in the Belgian study a dose escalation of capecitabine was administered twice daily (650 mg/m 2 or 850 mg/m 2 ) concomitantly with cetuximab and radiotherapy. 22 Patient baseline and tumor characteristics were comparable and whether the administration of capecitabine three weeks prior to cetuximab plus CRT leads to higher tumor downstaging in this setting requires further clinical investigation.
More recently a similar pCR (7.7%) was reported in LARC patients receiving neoadjuvant cetuximab given as a single dose and then combined with 5-FU and radiotherapy. 21 The addition of a second chemotherapeutic agent to neoadjuvant capecitabine-based CRT with cetuximab has not demonstrated a marked improvement to the rates of pCR or tumor downstaging in LARC, 24 which remain similar to those reported from studies of neoadjuvant capecitabine-based CRT, 12, 13, 25 or capecitabine-based CRT with irinotecan or oxaliplatin. 26, 27 In the present study an assessment of radiological tumor response according to RECIST criteria was made. An overall response rate of 71% was recorded, which was similar to the that reported for patients with locally advanced SCCHN receiving cetuximab in combination with radiotherapy. 18 The rates of tumor downstaging as determined by MRI and histopathological techniques were similar and reflected the findings from the MERCURY study where the two techniques were equivalent to 0.5 mm in the assessment of tumor spread in rectal cancer patients. 28 Recent studies have focused on the identification of predictive biomarkers for response to treatment with cetuximab. Data from randomized studies in mCRC patients suggest that tumor KRAS mutational status is predictive for response to cetuximab in combination with chemotherapy. 16, 17 In rectal cancer patients treated with cetuximab-based therapy, the frequency of TRG3-4 was reported to be higher (58% vs. 7.7%) in patients whose KRAS wild-type tumors had a high EGFR gene copy number compared with those tumors harboring a low EGFR gene copy number. 29 Debucquoy and colleagues suggest that decreased tumor proliferation observed in patients receiving an initial dose of cetuximab prior to CRT might affect the subsequent efficacy of capecitabine and RT leading to the low pCR reported. 22 Upregulated EGFR expression following the initial dose of cetuximab, and the presence of pro-inflammatory changes in tumors sampled at resection was associated with improved patient DFS, suggesting these to be potentially novel predictive markers of cetuximab-based treatment in this setting. 30 
Neoadjuvant cetuximab plus CRT on sphincter preservation rate
A secondary endpoint of this study was the SPR. All patients received definitive surgery, and 76% underwent sphincter preserving surgery, including 2/11 patients planned to receive abdominoperineal resection prior to neoadjuvant CRT. Within the group of patients receiving sphincter preserving surgery 53% had tumors located within 5 cm of the anal verge. Similar SPR have been reported in patients receiving capecitabine-based neoadjuvant CRT. 12, 13 However an improvement in the SPR in the preoperative CRT arm compared to radiotherapy alone arm has not been conclusively demonstrated in randomized studies. 5, 8 Toxicity and postoperative complications of cetuximab plus CRT
The combination of cetuximab with capecitabine-based CRT was generally well tolerated with the majority of patients completing the treatment protocol. The most common adverse event was grade 1/2 skin rash, which has also been described in other studies in mCRC investigating cetuximab, 16, 17 and was similar to that previously reported in LARC patients receiving neoadjuvant cetuximab plus CRT as was the frequency of grade 3 diarrhea (11%). 22 Radiodermatitis occurred in 16% of patients which was similar to that reported in locally advanced SSCHN where the addition of cetuximab to radiotherapy was found not to significantly increase the incidence of grade 3 radiodermatitis. 18 
Conclusion
In summary, neoadjuvant cetuximab in combination with capecitabine-based CRT in LARC was well tolerated and whilst pCR rates were not high, a high frequency of tumor downstaging was observed. To date, although preoperative CRT significantly improves local control in LARC, there is no improvement on overall survival compared with adjuvant therapy. To assess the value of EGFR-targeted agents in this setting, future randomized control trials should maybe evaluate the efficacy and safety of these agents with CRT on these endpoints and perhaps in patients assessed for potential predictive biomarkers of efficacy.
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